OBI licensed the worldwide therapeutic rights of OBI-858 to OBIGEN

1.Date of occurrence of the event:2023/12/20 2.Counterparty to the contract or commitment: OBIGEN Pharma, Inc. 3.Relationship with the Company: OBIGEN is a subsidiary held 52% of voting shares by the Company 4.Starting and ending dates (or rescission date) of the contract or commitment:2023/12/20 5.Major content (not applicable where rescinded): (1)To focus on the development of […]

This article is password protected.

To view the content, please enter your password in the field below